-
O.
Hahn,
Cynthia
Ma,
Ling
Lin,
D.
Hou,
H.
Sattar,
F.
Olopade,
R.
Nanda,
P.
Hoffman,
M.
Naughton,
T.
Pluard,
M.
Watson,
M.
Ellis,
S.
Conzen,
G.
Fleming
(2009)
A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
Cancer Research, 69
-
Xin
Zhang,
Hongzhen
Zhang,
M.
Tighiouart,
John
Lee,
H.
Shin,
F.
Khuri,
Chung
Yang,
Z.
Chen,
D.
Shin
(2008)
Synergistic inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐gallate and EGFR tyrosine kinase inhibitor
International Journal of Cancer, 123
-
(2011)
Combined Treatment in Triple-Negative Breast Cells www.aacrjournals.org
-
M.
Lund,
Katrina
Trivers,
P.
Porter,
R.
Coates,
B.
Leyland-Jones,
O.
Brawley,
E.
Flagg,
R.
O'Regan,
S.
Gabram,
J.
Eley
(2008)
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Breast Cancer Research and Treatment, 113
-
Xuerong
Wang,
N.
Hawk,
P.
Yue,
J.
Kauh,
S.
Ramalingam,
H.
Fu,
F.
Khuri,
Shi-Yong
Sun
(2008)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
Cancer Biology & Therapy, 7
-
N.
Sonenberg,
A.
Gingras
(1998)
The mRNA 5' cap-binding protein eIF4E and control of cell growth.
Current opinion in cell biology, 10 2
-
Xuerong
Wang,
P.
Yue,
Y.
Kim,
H.
Fu,
F.
Khuri,
Shi-Yong
Sun
(2008)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
Cancer research, 68 18
-
H.
Wendel,
Ricardo
Silva,
A.
Malina,
J.
Mills,
Hong
Zhu,
Takeshi
Ueda,
Rie
Watanabe‐Fukunaga,
R.
Fukunaga,
J.
Teruya-Feldstein,
J.
Pelletier,
S.
Lowe
(2007)
Dissecting eIF4E action in tumorigenesis.
Genes & development, 21 24
-
T.
Nielsen,
Forrest
Hsu,
Kristin
Jensen,
Maggie
Cheang,
G.
Karaca,
Zhiyuan
Hu,
T.
Hernandez-Boussard,
C.
Livasy,
D.
Cowan,
L.
Dressler,
L.
Akslen,
J.
Ragaz,
A.
Gown,
C.
Gilks,
M.
Rijn,
C.
Perou
(2004)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Clinical Cancer Research, 10
-
R.
O'Regan,
F.
André,
M.
Campone,
M.
Naughton,
C.
Manlius,
I.
Pylvaenaeinen,
T.
Sahmoud,
S.
Hurvitz
(2009)
RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.
Cancer Research, 69
-
L.
Carey,
C.
Perou,
C.
Livasy,
L.
Dressler,
D.
Cowan,
K.
Conway,
G.
Karaca,
M.
Troester,
C.
Tse,
S.
Edmiston,
Sandra
Deming,
J.
Geradts,
M.
Cheang,
T.
Nielsen,
P.
Moorman,
H.
Earp,
R.
Millikan
(2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
JAMA, 295 21
-
Bing-he
Xu
(2008)
Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer
Journal of Evidence-based Medicine
-
L.
Carey,
H.
Rugo,
P.
Marcom,
W.
Irvin,
M.
Ferraro,
E.
Burrows,
Xiaping
He,
C.
Perou,
E.
Winer
(2008)
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
Journal of Clinical Oncology, 26
-
M.
Copenhaver,
Blair
Johnson,
I-Ching
Lee,
J.
Harman,
M.
Carey
(2006)
Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy.
Journal of substance abuse treatment, 31 2
-
T.
Sørlie,
R.
Tibshirani,
Joel
Parker,
T.
Hastie,
J.
Marron,
A.
Nobel,
Shibing
Deng,
H.
Johnsen,
Robert
Pesich,
S.
Geisler,
J.
Demeter,
C.
Perou,
P.
Lønning,
P.
Brown,
A.
Børresen-Dale,
D.
Botstein
(2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
Proceedings of the National Academy of Sciences of the United States of America, 100
-
A.
Leo,
H.
Gómez,
Z.
Aziz,
Ž.
Zvirbule,
J.
Bines,
M.
Arbushites,
S.
Guerrera,
M.
Koehler,
C.
Oliva,
S.
Stein,
L.
Williams,
J.
Dering,
R.
Finn,
M.
Press
(2008)
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 34
-
J.
Bottorff,
Cecilia
Kalaw,
Joy
Johnson,
M.
Stewart,
L.
Greaves,
Joanne
Carey
(2006)
Couple dynamics during women's tobacco reduction in pregnancy and postpartum.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 8 4
-
MO
Lagravère,
Y.
Fang,
J.
Carey,
RW
Toogood,
GV
Packota,
PW
Major
(2006)
Density conversion factor determined using a cone-beam computed tomography unit NewTom QR-DVT 9000.
Dento maxillo facial radiology, 35 6
-
K.
O'reilly,
F.
Rojo,
Q.
She,
D.
Solit,
G.
Mills,
Debra
Smith,
H.
Lane,
F.
Hofmann,
D.
Hicklin,
D.
Ludwig,
J.
Baselga,
N.
Rosen
(2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer research, 66 3
-
(2011)
Mol Cancer Ther Molecular Cancer Therapeutics OF10
-
S.
Vukelja,
J.
O’Shaughnessy,
D.
Weckstein
(2007)
Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer
-
R.
Hudson,
Matthias
Laska,
T.
Berger,
B.
Heye,
J.
Schopohl,
A.
Danek
(1994)
Olfactory function in patients with hypogonadotropic hypogonadism: an all-or-none phenomenon?
Chemical senses, 19 1
-
M.
Dickler,
M.
Cobleigh,
K.
Miller,
P.
Klein,
E.
Winer
(2009)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Breast Cancer Research and Treatment, 115
-
(2013)
Author Manuscript
-
Shi-Yong
Sun,
L.
Rosenberg,
Xuerong
Wang,
Zhongmei
Zhou,
P.
Yue,
H.
Fu,
F.
Khuri
(2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer research, 65 16
-
T.
Chou,
P.
Talalay
(1984)
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
Advances in enzyme regulation, 22
-
J.
Reis-Filho,
A.
Tutt
(2007)
Triple negative tumours: a critical review
Histopathology, 52
-
J.
Baselga,
J.
Albanell,
A.
Ruíz,
A.
Lluch,
P.
Gascón,
V.
Guillem,
S.
González,
S.
Sauleda,
I.
Marimón,
J.
Tabernero,
M.
Koehler,
F.
Rojo
(2005)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 23
-
T.
Chou
(2006)
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
Pharmacological Reviews, 58
-
V.
Papadimitrakopoulou,
G.
Blumenschein,
N.
Leighl,
J.
Bennouna,
J.
Soria,
H.
Burris,
S.
Dimitrijević,
Tiffany
Kunz,
L.
Scala,
B.
Johnson
(2008)
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
Journal of Clinical Oncology, 26
-
(1998)
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet, 351
-
E.
Buck,
A.
Eyzaguirre,
E.
Brown,
F.
Petti,
Siobhan
McCormack,
J.
Haley,
K.
Iwata,
N.
Gibson,
Graeme
Griffin
(2006)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
Molecular Cancer Therapeutics, 5
-
F.
André,
K.
Slimane,
T.
Bachelot,
A.
Dunant,
M.
Namer,
Alain
Barrelier,
O.
Kabbaj,
J.
Spano,
H.
Marsiglia,
R.
Rouzier,
S.
Delaloge,
M.
Spielmann
(2004)
Breast cancer with synchronous metastases: trends in survival during a 14-year period.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
-
S.
Dawood,
K.
Broglio,
A.
Buzdar,
G.
Hortobagyi,
S.
Giordano
(2010)
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 1
-
Tumor volumes of MDA-MB-231 and MDA-MB-468 xenografts were measured twice weekly. Tumor sizes were compared among treatment groups
-
E.
Romond,
E.
Perez,
J.
Bryant,
V.
Suman,
C.
Geyer,
N.
Davidson,
E.
Tan-chiu,
S.
Martino,
S.
Paik,
P.
Kaufman,
S.
Swain,
T.
Pisansky,
L.
Fehrenbacher,
L.
Kutteh,
V.
Vogel,
D.
Visscher,
G.
Yothers,
R.
Jenkins,
A.
Brown,
S.
Dakhil,
E.
Mamounas,
W.
Lingle,
P.
Klein,
J.
Ingle,
N.
Wolmark
(2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
The New England journal of medicine, 353 16
-
E.
Laska,
M.
Meisner,
C.
Siegel
(1994)
Simple designs and model-free tests for synergy.
Biometrics, 50 3
-
(2007)
Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes